Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, tolerability, and pharmacokinetics study of AB928 in healthy volunteers
NL-OMON46373Phase 1Active, not recruiting
- Sponsor
- Arcus Biosciences
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etrumadenant in cancer (11 arms), sponsored by Arcus Biosciences. Primary endpoint: Safety and tolerability. Started Oct 2017; status: active, not recruiting.
02
Drugs
etrumadenant
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON46373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46373.